	US 11,707,441 B2
	Safinamide for treating myotonia
Jean-François Desaphy, Cellamare (IT); Sabata Pierno, Cellamare (IT); Diana Conte, Bari (IT); Elsa Melloni, Milan (IT); Silvia Vailati, Arcore (IT); Gloria Padoani, Locate Triulzi (IT); and Carla Caccia, Gallarate (IT)
Assigned to Zambon S.P.A., Bresso (IT)
Appl. No. 17/58,785
Filed by Zambon S.P.A., Bresso (IT)
PCT Filed May 28, 2019, PCT No. PCT/EP2019/063733 § 371(c)(1), (2) Date Nov. 25, 2020, PCT Pub. No. WO2019/229028, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. 18000481 (EP), filed on May 29, 2018.
Prior Publication US 2021/0196657 A1, Jul. 1, 2021
Int. Cl. A61K 31/165 (2006.01); A61P 21/00 (2006.01)

CPC A61K 31/165 (2013.01) [A61P 21/00 (2018.01)]

15 Claims

1. Method of treating myotonic disorders in patients in need thereof, said method comprising

administering to said patients a pharmaceutically effective amount of safinamide or a pharmaceutically acceptable salt thereof and treating said patients of said myotonic disorders, wherein the myotonic disorder is a non-dystrophic myotonia.